Chenhe Yi

Chenhe Yi

Auto-generated profile, based on publicly available information

Chenhe Yi

Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, PR China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2021 in Hepatology
Verified
Journal Article
Closed access
PDF file
CYChenhe Yi
Chenhe Yi
LCLirong Chen
Lirong Chen
ZLZhifei Ling
Zhifei Ling
LLLu Liu
Lu Liu
WSWeiqing Shao
Weiqing Shao
JCJinhong Chen
Jinhong Chen

6 December 2025 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
YMYue Ma
Yue Ma
CYChenhe Yi
Chenhe Yi
NCNing Cai
Ning Cai
BTBaorui Tao
Baorui Tao
YGYan Geng
Yan Geng
JCJinhong Chen
Jinhong Chen
The susceptibility to ferroptosis partially determines the efficacy of tyrosine kinase inhibitors (TKIs) in hepatocellular carcinoma (HCC), exposing a mechanistic vulnerability that can be therapeutically exploited. The development of deuterated compounds is a promising strategy for the improvement of anti-tumor efficacy. Here, we identified HCC with higher level of ferroptosis-resistance exhibited insensitive to TKIs, which could be reversed by deuterated TKIs. Aldehyde oxidase 1 (AOX1) was screened as a critical gene mediating the responsiveness to deuterated TKIs-induced ferroptosis in HCC. The presence of a pyridyl tri-deuterated methanamide contributed to the upregulation of AOX1 in a structure-dependent manner, thereby promoting ferroptosis. Mechanistically, AOX1 inhibited sirtuin 6-mediated deacetylation of H3K9 and H3K56, leading to transcriptional activation of acyl-CoA synthetase long chain family member 5, which resulted in poly-unsaturated fatty acids hyperaccumulation-induced ferroptosis. Additionally, HCC with lower AOX1 expression conferred better efficacy to deuterated TKIs. In patient cohorts with HCC, those with lower AOX1 expression exhibited a more pronounced therapeutic response to deuterated sorafenib. Overall, the present study elucidates the mechanism by which deuterated TKIs reverse TKI resistance by promoting ferroptosis and suggests that AOX1 could serve as a biomarker to guide clinical decision-making for deuterated TKI treatment in HCC.

17 July 2024 in Hepatology
Verified
Journal Article
Closed access
CYChenhe Yi
Chenhe Yi
LCLirong Chen
Lirong Chen
BTBaorui Tao
Baorui Tao
XWXiangyu Wang
Xiangyu Wang
JLJing Lin
Jing Lin
JCJinhong Chen
Jinhong Chen